No Compromise in MRI

Learn More

The individual who appears is for illustrative purposes. The person depicted is a model and not a real healthcare professional. US-N/A-2400043 05/24

Have a Question?
Print

Contrast ultrasound of liver or other area, e.g., a limited abdominal study

PostedJune 9, 2022
UpdatedSeptember 5, 2023

Q.

We have CPT® 76978 attached to our orders for ultrasound contrast injections of liver lesions. Are we also allowed to assign CPT code 76705 or does the CPT code 76978 also include the anatomic area scanned?

A.

CPT code 76978 is an ultrasound done with contrast [e.g., LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use. As such, it includes imaging of the liver or other body area imaged. Usually, a diagnostic ultrasound, such as a limited abdominal study (CPT code 76705), is done (without contrast) and, based on the findings, then the contrast enhanced exam (CPT code 76978) is ordered and performed. While this usually happens at a different session, it can occur at the same encounter and, based upon CCI edits, you would need to add modifier 59 or XU to the column 2 CPT code, 76705 to allow passing of the edit.

You must have separate orders, and two separate technical exams must be completed. The documentation in the medical record must clearly show the medical necessity for performing both in the same session.

The codes and full descriptions are as follows:

76978  Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion

76705   Ultrasound, abdominal, real time with image documentation; limited (e.g., single organ, quadrant, follow-up)

INDICATIONS AND USAGE | IMPORTANT SAFETY INFORMATION

LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use

Indications

LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is an ultrasound contrast agent indicated for use:

  • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
  • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
  • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

 

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration.

  • Assess all patients for the presence of any condition that precludes administration
  • Always have resuscitation equipment and trained personnel readily available

 

Contraindications

LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is contraindicated in patients with known or suspected hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (PEG).

Warnings

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including LUMASON. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to LUMASON administration and monitor all patients for acute reactions.

Post-marketing hypersensitivity reactions, including serious hypersensitivity reactions, have been observed during use or shortly following LUMASON administration. These reactions may occur in patients with no history of prior exposure to sulfur hexafluoride lipid-containing microspheres. LUMASON contains PEG. There may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG.

Systemic embolization may occur in patients with cardiac shunts. Assess patients with cardiac shunts for embolic phenomena following LUMASON administration.

There is a risk of ventricular arrhythmia related to high mechanical index in patients administered LUMASON. LUMASON is not recommended for use at mechanical indices greater than 0.8.

The most common adverse reactions (incidence ≥ 0.5%) are headache (1%) and nausea (0.5%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information for LUMASON ultrasound contrast agent, including BOXED WARNING on Serious Cardiopulmonary Reactions.

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). 

LUMASON is a registered trademark of Bracco Diagnostics Inc.